 |
| About Bioline | All Journals | Testimonials | Membership | News |
|
||||||
|
||||||
Revista Biotecnologia Aplicada 12(2): 87 (1995) REPORTE CORTO/SHORT REPORT Presented in the Congress Biotecnologia Habana'94. La Habana, Cuba, Nov. 28 - Dec. 3, 1994 PASSIVE IMMUNE GLOBULIN THERAPY AND ITS POTENTIAL FOR REDUCING VIRAL BURDEN
N. Haigwood1, A. Watson1, J. McClure1, W. Sutton1, J. Ranchalis1, T. Wrey1, B. Travis1, S-L. Hu1, G.Voss2, N. Letvin2, V. Hirsch3, P. Johnson4 and A. Lewis4.
1Bristol Myers Squibb Seattle, WA; 2Harvard University, MA; 3NAID, NIH, MD; 4Ohio State University, OH.
Code Number: BA95028
File Sizes:
Text: 3K
No associated graphics
The objective of this ongoing study is to test the efficacy of
antibodies (IgG) purified from an SIV-infected long-term
surviving macaque (SIVIG) to affect the time course of magnitude
of primary viremia and disease outcome in newly infected animals.
Sixteen M. mulatta were infected with a macaque grown
stock of SIVsmE660; and 6 treated with SIVIG, 6 with normal Ig
(NIG) and 4 controls left untreated. SIVIG and NIG were
administered 24 hours and two weeks post infection (PI) at 170
mg/kg. Animals are being monitored for infection by quantitative
virus culture, QC-PCR of plasma virus, and p27 antigenemia, for
immune responses, and for disease. Levels of reconstituted IgG
throughout the first 6 weeks PI were equivalent to levels
generated in control animals at 8 weeks PI. Antigenemia (p27)
peaked at weeks 2-3 in the infected controls and was not detected
in the SIVIG-treated group during primary viremia due to antibody
binding to the free virus. De novo anti-SIV antibody production
was delayed to week 12 in the SIVIG-treated group, suggesting
that the SIVIG obscured the virus from the immune system.Cumulative virus loads measured by RNA-PCR were 4 to 6-fold lower in the SIVIG-treated animals than in the controls. Plasma viremia was an excellent predictor of disease progression. Post-acute plasma viremia was cleared for at least 20 weeks in most of the SIVIG-treated animals, and there is no sign of disease in these animals; no clearance was seen in the controls. Resolution of primary viremia in the SIVIG group in the absence of de novo antibodies suggests that clearance is mediated by SIVIG alone or in combination with cell mediated immunity. The results of this experiment should elucidate the role of humoral immunity in controlling viremia and disease, as well as provide data for the efficacy of passive immune globulin therapy. Copyright 1995 Sociedad Iberolatinoamericana de Biotecnologia Aplicada a la Salud
|
| |||||||||
